{"id":476422,"date":"2020-03-26T13:44:01","date_gmt":"2020-03-26T13:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476422"},"modified":"2020-03-26T13:44:01","modified_gmt":"2020-03-26T13:44:01","slug":"bipolar-disorder-pipeline-upcoming-therapies-anticipated-to-enter-bipolar-disorder-market-in-coming-years","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-disorder-pipeline-upcoming-therapies-anticipated-to-enter-bipolar-disorder-market-in-coming-years_476422.html","title":{"rendered":"Bipolar Disorder Pipeline: Upcoming therapies anticipated to enter Bipolar disorder market in coming years"},"content":{"rendered":"
\"Bipolar<\/a><\/p>\n
\n
Bipolar Disorder Pipeline<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Bipolar Disorder Pipeline Report” delivers an in-depth understanding of the Disorder- with present treatment algorithm, therapies available, and in the pipeline along with their clinical phases, market launch, and market trends and forecast analysis with the shift in trends in the 7MM during 2017-30. <\/div>\n

 <\/p>\n

 <\/strong><\/p>\n

Bipolar Disorder (Manic depression) is categorized by recurrent-shifts in the mood\/temper and is a manic-depressive disorder hindering the routine life of an individual.<\/p>\n

The American Psychiatric Association categorizes Bipolar disorder into four major types of bipolar disorder: Bipolar I disorder, Bipolar II disorder, Cyclothymic disorder, and Bipolar disorder due to another medical or substance abuse disorder.<\/p>\n

 <\/strong><\/p>\n

The origin of Bi-polar disorder is still uncertain.<\/strong><\/p>\n

 <\/strong><\/p>\n

DelveInsight’s “Bipolar Disorder (Manic Depression) Pipeline Insight, 2020<\/a>” report <\/strong>delivers an in-depth view of the current clinical development trends and growth projections in the Bipolar Disorder market.<\/p>\n

The report covers Bipolar disorder pipeline landscape including treatment guidelines, commercial assessment and clinical evaluation. The report offers all the products from the pre-clinical developmental phase to the marketed phase, with an all-inclusive description of the drug, mechanism of action, clinical studies, NDA approvals (if any), and product development activities.<\/p>\n

The Bipolar disorder pipeline report also sheds light on the novel technologies, Bipolar disorder partnerships, licensing, mergers and acquisition, funding, titles\/labels, and other product-related details.<\/p>\n

 <\/p>\n

Know more about the report<\/a>.<\/p>\n

 <\/p>\n

Current Bipolar disorder treatment scenario and a strong pipeline <\/strong><\/p>\n

FDA-approved agents for the acute treatment of bipolar depression include Olanzapine-fluoxetine combination, Lurasidone, and Quetiapine. <\/strong><\/p>\n

Other off-label therapies present in the Bipolar disorder market are Anticonvulsants (such as Divalproex and lamotrigine), olanzapine monotherapy, and Lithium and lamotrigine combined therapy.<\/p>\n

Key Companies and Drugs <\/strong>driving Bipolar disorder market forward are Lundbeck and Otsuka Pharmaceutical (Brexpiprazole<\/strong>), Intra-Cellular Therapies (Lumateperone<\/strong> (ITI-007)), Sage Therapeutics (Sage-217<\/strong>) and several others.<\/p>\n

 <\/p>\n

Request for Sample pages.<\/a><\/p>\n

 <\/p>\n

Report Highlights <\/strong><\/p>\n